October 8, 2025 — FacialDx, Inc. is proud to announce a major milestone in its growth and clinical advancement strategy: a strengthened alliance with Synbio International, Inc., formalized through a Share Purchase Agreement and Warrant Agreement. This expanded partnership deepens collaboration between the two organizations and aligns both for long-term success in advancing non-invasive, AI-driven health diagnostics.
A Deeper Partnership for Innovation
Under the terms of the agreement, Synbio International has acquired 100,000 Class A shares of FacialDx, becoming an equity holder and gaining indirect participation in FacialDx’s intellectual property. In addition, Synbio may convert up to $2.5 million in future clinical trial expenditures into additional FacialDx shares, reflecting a shared commitment to research, validation, and regulatory progress.
The companies will also form a Joint Trial Committee (JTC) responsible for overseeing the design, conduct, and reporting of clinical trials — a key step toward FDA approval. This structure ensures scientific rigor, transparency, and alignment of strategic goals across both teams.
Furthermore, FacialDx will gain the right to acquire Synbio’s common stock upon FDA approval, reinforcing mutual confidence in the technology and its market potential.
Combining Strengths: AI Meets Clinical Science
This collaboration integrates FacialDx’s cutting-edge AI facial analysis platform with Synbio’s deep clinical and regulatory expertise. FacialDx’s technology analyzes subtle micro-expressions, facial cues, and physiological markers to detect early signs of health concerns — offering a non-invasive, rapid, and scalable tool for pre-screening and monitoring conditions related to:
- Mental health and emotional well-being
- Traumatic brain injury (TBI)
- Chronic pain and fatigue
- Sleep and performance disorders
By combining these strengths, the partnership aims to deliver validated, FDA-approved digital diagnostics that empower clinicians, improve early detection, and expand access to precision health tools worldwide.
A Shared Vision for the Future of Digital Health
The expanded partnership with Synbio marks a defining step in FacialDx’s mission to make AI-based facial health analysis a trusted clinical standard. Both companies are aligned in their vision to bring innovation, integrity, and accessibility to the intersection of technology and medicine.
“This alliance represents more than investment — it’s a validation of our shared belief that AI can bridge critical gaps in healthcare,” said a FacialDx spokesperson. “With Synbio’s clinical expertise and our AI innovation, we’re positioned to advance faster toward FDA approval and real-world impact.”
As the Joint Trial Committee begins its next phase of work, FacialDx and Synbio will continue to share updates on clinical milestones, FDA progress, and commercialization plans.
